Pharmacogenetics of Ophthalmic Topical Beta-blockers

Overview

Journal Per Med

Specialties General Medicine
Genetics

Date 2009 Mar 7

PMID 19266054

Citations 5

Authors

Duska J Sidjanin

Catherine A McCarty

Richard Patchett

Edward Smith

Russell A Wilke

Affiliations

Soon will be listed here.

Abstract

Glaucoma is the second leading cause of blindness worldwide. The primary glaucoma risk factor is elevated intraocular pressure. Topical beta-blockers are affordable and widely used to lower intraocular pressure. Genetic variability has been postulated to contribute to interpersonal differences in efficacy and safety of topical beta-blockers. This review summarizes clinically significant polymorphisms that have been identified in the beta-adrenergic receptors (ADRB1, ADRB2 and ADRB3). The implications of polymorphisms in CYP2D6 are also discussed. Although the candidate-gene approach has facilitated significant progress in our understanding of the genetic basis of glaucoma treatment response, most drug responses involve a large number of genes, each containing multiple polymorphisms. Genome-wide association studies may yield a more comprehensive set of polymorphisms associated with glaucoma outcomes. An understanding of the genetic mechanisms associated with variability in individual responses to topical beta-blockers may advance individualized treatment at a lower cost.

Citing Articles

The Identification of New Pharmacological Targets for the Treatment of Glaucoma: A Network Pharmacology Approach.

Giuffrida E, Platania C, Lazzara F, Conti F, Marcantonio N, Drago F Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458974 PMC: 11509888. DOI: 10.3390/ph17101333.

Gene therapy for glaucoma: Targeting key mechanisms.

Henderson J, OCallaghan J, Campbell M Vision Res. 2024; 225:108502.

PMID: 39423611 PMC: 11579448. DOI: 10.1016/j.visres.2024.108502.

Genotype and Phenotype Influence the Personal Response to Prostaglandin Analogues and Beta-Blockers in Spanish Glaucoma and Ocular Hypertension Patients.

Opazo-Toro V, Fortuna V, Jimenez W, Pazos Lopez M, Royo M, Ventura-Abreu N Int J Mol Sci. 2023; 24(3).

PMID: 36768422 PMC: 9916755. DOI: 10.3390/ijms24032093.

Repurposing Ophthalmologic Timolol for Dermatologic Use: Caveats and Historical Review of Adverse Events.

Yoon D, Kaur R, Gallegos A, West K, Yang H, Schaefer S Am J Clin Dermatol. 2020; 22(1):89-99.

PMID: 33237496 DOI: 10.1007/s40257-020-00567-3.

In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma.

Martinez T, Gonzalez M, Roehl I, Wright N, Paneda C, Jimenez A Mol Ther. 2013; 22(1):81-91.

PMID: 24025749 PMC: 3978804. DOI: 10.1038/mt.2013.216.

References

McLaren N, Moroi S . Clinical implications of pharmacogenetics for glaucoma therapeutics. Pharmacogenomics J. 2003; 3(4):197-201. DOI: 10.1038/sj.tpj.6500181. View

Nieminen T, Uusitalo H, Maenpaa J, Turjanmaa V, Rane A, Lundgren S . Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. Eur J Clin Pharmacol. 2005; 61(11):811-9. DOI: 10.1007/s00228-005-0052-4. View

Stoilov I, Akarsu A, Sarfarazi M . Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum Mol Genet. 1997; 6(4):641-7. DOI: 10.1093/hmg/6.4.641. View

Zimmerman T, Harbin R, Pett M, Kaufman H . Timolol and facility of outflow. Invest Ophthalmol Vis Sci. 1977; 16(7):623-4. View

Idrees F, Vaideanu D, Fraser S, Sowden J, Khaw P . A review of anterior segment dysgeneses. Surv Ophthalmol. 2006; 51(3):213-31. DOI: 10.1016/j.survophthal.2006.02.006. View

Resnikoff S, Pascolini D, Etyaale D, Kocur I, Pararajasegaram R, Pokharel G . Global data on visual impairment in the year 2002. Bull World Health Organ. 2005; 82(11):844-51. PMC: 2623053. DOI: /S0042-96862004001100009. View

Wilke R, Reif D, Moore J . Combinatorial pharmacogenetics. Nat Rev Drug Discov. 2005; 4(11):911-8. DOI: 10.1038/nrd1874. View

Moore J, Mason D, Green S, Hsu J, Liggett S . Racial differences in the frequencies of cardiac beta(1)-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C. Hum Mutat. 1999; 14(3):271. DOI: 10.1002/(SICI)1098-1004(1999)14:3<271::AID-HUMU14>3.0.CO;2-Q. View

Wiggs J, Vollrath D . Molecular and clinical evaluation of a patient hemizygous for TIGR/MYOC. Arch Ophthalmol. 2001; 119(11):1674-8. DOI: 10.1001/archopht.119.11.1674. View

10.

Rau T, Heide R, Bergmann K, Wuttke H, Werner U, Feifel N . Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics. 2002; 12(6):465-72. DOI: 10.1097/00008571-200208000-00007. View

11.

McCarty C, Wilke R, Giampietro P, Wesbrook S, Caldwell M . Marshfield Clinic Personalized Medicine Research Project (PMRP): design, methods and recruitment for a large population-based biobank. Per Med. 2018; 2(1):49-79. DOI: 10.1517/17410541.2.1.49. View

12.

Taylor M . Pharmacogenetics of the human beta-adrenergic receptors. Pharmacogenomics J. 2006; 7(1):29-37. DOI: 10.1038/sj.tpj.6500393. View

13.

Enyedi L, Freedman S . Latanoprost for the treatment of pediatric glaucoma. Surv Ophthalmol. 2002; 47 Suppl 1:S129-32. DOI: 10.1016/s0039-6257(02)00303-x. View

14.

Eichelbaum M, Ingelman-Sundberg M, Evans W . Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006; 57:119-37. DOI: 10.1146/annurev.med.56.082103.104724. View

15.

Fleming C, Whitlock E, Beil T, Smit B, Harris R . Screening for primary open-angle glaucoma in the primary care setting: an update for the US preventive services task force. Ann Fam Med. 2005; 3(2):167-70. PMC: 1466856. DOI: 10.1370/afm.293. View

16.

Lanfear D, Jones P, Marsh S, Cresci S, McLeod H, Spertus J . Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA. 2005; 294(12):1526-33. DOI: 10.1001/jama.294.12.1526. View

17.

Suzuki Y, Shirato S, Taniguchi F, Ohara K, Nishimaki K, Ohta S . Mutations in the TIGR gene in familial primary open-angle glaucoma in Japan. Am J Hum Genet. 1997; 61(5):1202-4. PMC: 1716051. DOI: 10.1086/301612. View

18.

Edeki T, He H, Wood A . Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. JAMA. 1995; 274(20):1611-3. View

19.

Turki J, Pak J, Green S, Martin R, Liggett S . Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest. 1995; 95(4):1635-41. PMC: 295666. DOI: 10.1172/JCI117838. View

20.

Alward W . Medical management of glaucoma. N Engl J Med. 1998; 339(18):1298-307. DOI: 10.1056/NEJM199810293391808. View